IBIO
iBio, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
1.43
▼ 0.04 (2.72%)
MARKET · —
Price
Open
1.50
Prev close
1.47
Day high
1.50
Day low
1.42
Volume
749.23K
Market cap
—
P/E (TTM)
—
52W range
0.76 – 3.82
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
+2.14%
-1.6%
3M
-24.34%
-27.4%
6M
-39.92%
-51.0%
YTD
-25.91%
-38.2%
1Y
+88.16%
+68.2%
3Y
-82.56%
-156.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.45
-1.11% from price
SMA 20
1.43
+0.25% from price
SMA 50
1.51
-5.11% from price
SMA 100
1.67
-14.13% from price
SMA 200
1.84
-22.20% from price
EMA 12
1.44
-0.90% from price
EMA 26
1.45
-1.61% from price
EMA 50
1.52
-5.65% from price
RSI (14)
46.9
Neutral
MACD (12,26,9)
-0.01
Hist 0.01
ATR (14)
0.08
5.34% of price
Realised vol 30D
41.5%
Annualised
Bollinger upper
1.50
20, 2σ
Bollinger lower
1.36
20, 2σ
50 / 200 cross
Death
1.51 vs 1.84
Trend bias
Below 200
-22.20%
Risk profile
Beta vs SPY
2.06
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
41.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-56.0%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.08
5.34% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
GlobeNewswire · 18d ago
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
GlobeNewswire · 52d ago
Could iBio (IBIO) Be an Underrated Obesity Stock?
Insider Monkey · 72d ago
B. Riley Initiates iBio at Buy With $6 Price Target
MT Newswires · 78d ago
iBio to Participate in Upcoming Healthcare Investor Conferences
GlobeNewswire · 81d ago
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
GlobeNewswire · 81d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.